| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Monday, November 16, 2026 08:01 AM
Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases ...
|
|
Monday, November 16, 2026 04:17 AM
O principal medicamento candidato da Windward Bio, o WIN378, é um anticorpo monoclonal experimental de ação ultralonga que tem como alvo a linfopoietina estromal tímica (TSLP), uma proteína envolvida ...
|
|
Monday, November 16, 2026 03:36 AM
Windward Bio (NASDAQ:WWB), a clinical-stage biotechnology company developing treatments for chronic inflammatory diseases, completed its first day of trading on the Nasdaq on November 13, 2026, with ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/11/26 | 25.00 | 32.00 | 22.50 | 30.04 | 237,639 |
|
|
||||
|
|
||||
|
|